The study showed a significant decrease in the expression of ABCG2 mRNA in the primary tumor tissue (about 100-fold compared with normal tissue), and about a five-fold increase in ABCG2 mRNA expression in the metastases from irinotecan-treated patients. This evidence concerns the gene ABCG2 and neoplasm.